GlassScriptPhysician profile
Kimberly Keech
NPI 1770190530
$3,202.32
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $1,384 · 2023: $1,508 · 2024: $65.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.36 | 2022-2024 | |
| Viiv Healthcare Company | $337.88 | 2022-2023 | Apretude |
| Glaxosmithkline, LLC. | $295.04 | 2022-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $270.35 | 2022-2023 | Mounjaro |
| Neurocrine Biosciences, INC. | $233.09 | 2023 | Ingrezza |
| Genentech USA, INC. | $218.49 | 2021-2023 | Evrysdi |
| Astrazeneca Pharmaceuticals LP | $191.91 | 2022-2023 | Breztri, Farxiga |
| Paratek Pharmaceuticals, INC. | $157.43 | 2023 | Nuzyra |
| Novo Nordisk INC | $128.95 | 2021-2022 | |
| Shield Therapeutics INC | $124.99 | 2023 | Accrufer |
| Genzyme Corporation | $122.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $106.37 | 2023 | |
| Antares Pharma, INC. | $102.00 | 2023 | Nocdurna, Xyosted, Tlando |
| Biogen, INC. | $82.61 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $79.01 | 2023 | |
| Gilead Sciences, INC. | $45.10 | 2022 | |
| Organon LLC | $31.29 | 2022 | |
| Janssen Biotech, INC. | $27.58 | 2024 | Stelara |
| Ardelyx, INC. | $20.24 | 2024 | Ibsrela |
| Acerus Pharmaceuticals Corporation | $19.17 | 2022 | |
| Clarus Therapeutics INC. | $18.44 | 2021 | |
| Tolmar, INC. | $16.32 | 2023 | |
| Phadia US INC. | $15.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Keech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.